Scholarlink

Background <p>Glioblastoma remains highly lethal despite current standards, driving interest in vaccine-based immunotherapy to improve survival. Given variability in outcomes and uncertainty regarding optimal vaccine platforms, we conducted&#xa0;a time-to-event meta-analysis.</p> Methods <p>We conducted a database search for head-to-head phase II and III trials published through July 9, 2025, that assessed vaccine-based cancer immunotherapy in adults with newly diagnosed glioblastoma. Pseudo-individual data were digitized and reconstructed with the IPDfromKM method from survival curves. Primary endpoints of this study were overall survival (OS) and progression-free survival (PFS). This study was registered with PROSPERO, CRD420251231284.</p> Results <p>Initial search yielded 1248 articles, of which 5 randomized trials (696 patients: 358 vaccine and 338 control) met inclusion. Mean age ranged from 56.6–61.6&#xa0;years, and 53.7% of participants had a Karnofsky Performance Status ≥ 90. In the primary analysis, vaccination did not significantly reduce the risk of death (HR 0.95; 95%CI 0.81–1.13) or disease progression (HR 0.96; 95%CI 0.82–1.12). In subgroup analyses, patients who underwent gross total resection and received vaccinations had improved OS compared with similarly resected controls (HR 0.50; 95%CI 0.31–0.81), and dendritic cell vaccines were associated with a PFS advantage (HR 0.73; 95%CI 0.56–0.96).</p> Conclusion <p>In this study, vaccinations did not significantly improve survival in adult patients with newly diagnosed glioblastoma. Gross total resection, however, seems to be associated with OS benefit of vaccinations. There is a need for more head-to-head clinical trials to supplement the available evidence.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Vaccine-based cancer immunotherapy in newly diagnosed glioblastoma: a time-to-event meta-analysis of phase II and III randomized controlled trials

  • 期刊论文

  • 发表日期：

    2026年7月25日

查看全文
  • Kwadwo Darko,
  • Pearl Tenkorang,
  • Godfred Junior Osei-Tutu,
  • Olivia Asiedu,
  • Marjidah Tahiru,
  • Princess Nkrumah-Boateng,
  • Jianan Chen,
  • Ekokobe Fonkem,
  • Arnold B. Etame

摘要

Background

Glioblastoma remains highly lethal despite current standards, driving interest in vaccine-based immunotherapy to improve survival. Given variability in outcomes and uncertainty regarding optimal vaccine platforms, we conducted a time-to-event meta-analysis.

Methods

We conducted a database search for head-to-head phase II and III trials published through July 9, 2025, that assessed vaccine-based cancer immunotherapy in adults with newly diagnosed glioblastoma. Pseudo-individual data were digitized and reconstructed with the IPDfromKM method from survival curves. Primary endpoints of this study were overall survival (OS) and progression-free survival (PFS). This study was registered with PROSPERO, CRD420251231284.

Results

Initial search yielded 1248 articles, of which 5 randomized trials (696 patients: 358 vaccine and 338 control) met inclusion. Mean age ranged from 56.6–61.6 years, and 53.7% of participants had a Karnofsky Performance Status ≥ 90. In the primary analysis, vaccination did not significantly reduce the risk of death (HR 0.95; 95%CI 0.81–1.13) or disease progression (HR 0.96; 95%CI 0.82–1.12). In subgroup analyses, patients who underwent gross total resection and received vaccinations had improved OS compared with similarly resected controls (HR 0.50; 95%CI 0.31–0.81), and dendritic cell vaccines were associated with a PFS advantage (HR 0.73; 95%CI 0.56–0.96).

Conclusion

In this study, vaccinations did not significantly improve survival in adult patients with newly diagnosed glioblastoma. Gross total resection, however, seems to be associated with OS benefit of vaccinations. There is a need for more head-to-head clinical trials to supplement the available evidence.